Kiniksa Pharmaceuticals International, plc Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Kiniksa Pharmaceuticals International, plc (KNSA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $14.69 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2024-02-28
- Kiniksa Pharmaceuticals International, plc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $14.69, a 29.20% increase from fiscal 2022.
- Kiniksa Pharmaceuticals International, plc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $11.37, a 32.96% decline from fiscal 2021.
- Kiniksa Pharmaceuticals International, plc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $16.96, a 2.79% increase from fiscal 2020.
- Kiniksa Pharmaceuticals International, plc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2020 was $16.50.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2023-12-31 | $14.69 10-K · filed 2024-02-28 |
| 2022-12-31 | $11.37 10-K · filed 2023-03-02 |
| 2021-12-31 | $16.96 10-K · filed 2022-02-24 |
| 2020-12-31 | $16.50 10-K · filed 2021-02-25 |